AllPeptides.eu - Advanced Peptide Research
    Single Peptides
    Bioregulator

    Ovagen (20mg)

    Subcutaneous injectionDaily20mg

    Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16

    🇷🇺 МЗ РФ (Оваген®)

    Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.

    Approved by select regulatory agencies — not FDA/EMA
    Educational information. Not medical advice or a recommendation for use.

    ⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer

    Free Access

    How It Works

    Ovagen epigenetically regulates gene expression in the cells of the gastrointestinal mucosa and the liver, improving digestive function, nutrient absorption, and intestinal barrier integrity.

    Quick Start

    • Typical Dose: 1–2mg subcutaneously
    • Frequency: Daily for 10–20 days
    • Storage: 2–8°C after reconstitution
    Detailed Protocol Data

    Dosing Table — Ovagen 20mg

    Educational only
    Vial Size— affects syringe units
    BAC Water2 mL
    Concentration10.00 mg/mL

    Route: Subcutaneous injection | Frequency: Daily

    WeekDoseUnits (per injection)
    1–2
    1mg
    10 Units (0.10 mL)
    3+
    2mg
    20 Units (0.20 mL)

    10–20 day cycle, repeat every 3–6 months.

    Related compounds

    Reconstitution Steps

    1. Clean the vial stoppers with an alcohol swab.
    2. Withdraw 2mL of bacteriostatic water.
    3. Slowly inject down the side of the vial wall.
    4. Gently swirl until fully dissolved.
    5. Store in the refrigerator (2–8°C).

    Protocol Overview

    • Gastrointestinal/hepatic system bioregulator.
    • Epigenetic regulation of digestive function genes.
    • Used in gastrointestinal repair protocols.

    Dosing Protocol

    • 1–2mg/day for 10–20 days.
    • Repeat every 3–6 months.
    • Combines with Chonluten or Cartalax.
    • Break between cycles: After the cycle (10–20 days), a washout period of 3–6 months is recommended. Khavinson bioregulator peptides — typically 2–3 cycles/year.

    Washout & Cycle Restart

    When can I restart?

    After the cycle (10–20 days), a washout period of 3–6 months is recommended. Khavinson bioregulator peptides — typically 2–3 cycles/year.

    Minimum wait period: 12 weeks

    Storage Instructions

    • Reconstituted: 2–8°C, use within 21 days.
    • Powder: 2–8°C.

    Important Notes

    • Cumulative action — effects seen after the cycle.
    • Low side effect profile.
    Clinical Analysis & Safety

    Potential Benefits & Side Effects

    Potential Benefits:

    • Improved digestive function
    • Intestinal barrier support
    • Hepatoprotection
    • Anti-aging action on the GI tract

    Potential Side Effects:

    • Mild injection site irritation
    • Rarely: transient digestive disturbances

    ⚠️ Serious Warnings & Long-Term Risks

    The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.

    🫁 Hepatic
    🟡 Moderate / Theoretical

    GI bioregulator — limited data

    Targets the hepatodigestive system. No independent safety data. Possible interaction with hepatic drug metabolism.

    📄 Khavinson VK — Peptide Bioregulation

    References

    1. Khavinson Bioregulators — Khavinson VK. Peptides and Ageing. Neuroendocrinol Lett. 2002;23 Suppl 3:11-144.
      View Source
    2. Short peptides and hepatocyte function — Khavinson VK, et al. Bull Exp Biol Med. 2008;146(1):110-113.
      View Source

    Recommended Supplements

    Research Sources & Verified Data
    …
    Clinical Trials
    …
    PubMed Studies
    Research-only
    FDA Status
    1
    Regulatory Approvals
    Verified across ClinicalTrials.gov, PubMed & FDA

    External Sources & Regulatory Status

    Regulatory Approvals

    🇷🇺
    МЗ РФ
    Approved

    Оваген® · Hepatogastrointestinal (2007)

    Approved in Russia (Khavinson bioregulator)

    No official regulatory source available yet — research peptide.

    Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.

    Summary:
    1 Approvals
    0 PubMed
    0 Clinical Studies

    Continue Your Research

    Explore tools and guides related to this protocol.

    Educational contentRegularly reviewed & maintainedEvidence-based review

    Important Disclaimer

    The content of this website is provided exclusively for informational and educational purposes within the context of research literature.

    Read the full Disclaimer →

    Educational Navigator

    Educational reading navigator

    Find where to start in research peptide science through evidence, safety context and regulatory awareness.

    Covers

    Evidence levelsSafety contextRegulatory overviewLiterature readingResearch methodEducational reports
    5 min readEvidence-firstOpen access
    Open evidence framework

    New knowledge, new tools and selected updates from AllPeptides.eu